tiprankstipranks
AnaptysBio Inc (MX:ANAB)
:ANAB
Mexico Market
ANAB
AnaptysBio
RESEARCH TOOLSreports

AnaptysBio (ANAB) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ANAB Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
AnaptysBio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ANAB Stock 12 Month Forecast

Average Price Target

$1,438.71
▲(115.38% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $1,438.71 with a high forecast of $1,612.71 and a low forecast of $1,273.19. The average price target represents a 115.38% change from the last price of $668.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"518":"$518","1613":"$1,613","791.75":"$791.8","1065.5":"$1,065.5","1339.25":"$1,339.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1612.7115621,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.61K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1438.7084725050001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.44K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1273.1933385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.27K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[518,791.75,1065.5,1339.25,1613],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,668,740.6701201615384,813.340240323077,886.0103604846154,958.6804806461539,1031.3506008076924,1104.0207209692308,1176.6908411307693,1249.3609612923078,1322.0310814538461,1394.7012016153847,1467.3713217769232,1540.0414419384615,{"y":1612.7115621,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,668,727.2852671157692,786.5705342315384,845.8558013473078,905.141068463077,964.4263355788462,1023.7116026946155,1082.9968698103849,1142.282136926154,1201.567404041923,1260.8526711576924,1320.1379382734617,1379.423205389231,{"y":1438.7084725050001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,668,714.5533337307693,761.1066674615384,807.6600011923077,854.2133349230769,900.7666686538462,947.3200023846155,993.8733361153846,1040.4266698461538,1086.980003576923,1133.5333373076924,1180.0866710384616,1226.640004769231,{"y":1273.1933385,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":519.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":668,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,613Average Price Target$1,439Lowest Price Target$1,273
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on MX:ANAB
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Assigned
08/25/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and AnaptysBio (NASDAQ: ANAB)
H.C. Wainwright Analyst forecast on MX:ANAB
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$1,612.71
Buy
141.42%
Upside
Reiterated
08/24/26
Jemperli Priority Review and Litigation Update Reinforce AnaptysBio Buy Rating with Unchanged $95 Price Target
Barclays Analyst forecast on MX:ANAB
Etzer Darout
Barclays
Barclays
$1,273.19
Buy
90.60%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)
Piper Sandler Analyst forecast on MX:ANAB
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$1,578.76
Buy
136.34%
Upside
Reiterated
07/21/26
UBS Analyst forecast on MX:ANAB
Michael Yee
UBS
UBS
$1,290.17
Buy
93.14%
Upside
Reiterated
06/30/26
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)
Leerink Partners Analyst forecast on MX:ANAB
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)
J.P. Morgan Analyst forecast on MX:ANAB
Anupam Rama
J.P. Morgan
J.P. Morgan
$1,171.34→$1,188.31
Buy
77.89%
Upside
Reiterated
05/22/26
J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)
Wedbush Analyst forecast on MX:ANAB
David Nierengarten
Wedbush
Wedbush
$1,018.55→$1,273.19
Buy
90.60%
Upside
Reiterated
03/31/26
Wedbush Remains a Buy on AnaptysBio (ANAB)
Truist Financial Analyst forecast on MX:ANAB
Joon Lee
Truist Financial
Truist Financial
$611.13→$848.8
Hold
27.07%
Upside
Reiterated
03/09/26
Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)
Guggenheim Analyst forecast on MX:ANAB
Yatin Suneja
Guggenheim
Guggenheim
$2,376.63
Buy
255.78%
Upside
Reiterated
03/04/26
Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Wells Fargo Analyst forecast on MX:ANAB
Derek Archila
Wells Fargo
Wells Fargo
$1,375.05
Buy
105.85%
Upside
Reiterated
12/16/25
AnaptysBio (ANAB) Receives a Buy from Wells Fargo
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen Analyst forecast on MX:ANAB
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Assigned
08/25/26
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and AnaptysBio (NASDAQ: ANAB)
H.C. Wainwright Analyst forecast on MX:ANAB
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$1,612.71
Buy
141.42%
Upside
Reiterated
08/24/26
Jemperli Priority Review and Litigation Update Reinforce AnaptysBio Buy Rating with Unchanged $95 Price Target
Barclays Analyst forecast on MX:ANAB
Etzer Darout
Barclays
Barclays
$1,273.19
Buy
90.60%
Upside
Reiterated
07/31/26
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (NYSE: MTD), AnaptysBio (NASDAQ: ANAB) and Alnylam Pharma (NASDAQ: ALNY)
Piper Sandler Analyst forecast on MX:ANAB
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$1,578.76
Buy
136.34%
Upside
Reiterated
07/21/26
UBS Analyst forecast on MX:ANAB
Michael Yee
UBS
UBS
$1,290.17
Buy
93.14%
Upside
Reiterated
06/30/26
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)
Leerink Partners Analyst forecast on MX:ANAB
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)
J.P. Morgan Analyst forecast on MX:ANAB
Anupam Rama
J.P. Morgan
J.P. Morgan
$1,171.34→$1,188.31
Buy
77.89%
Upside
Reiterated
05/22/26
J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)
Wedbush Analyst forecast on MX:ANAB
David Nierengarten
Wedbush
Wedbush
$1,018.55→$1,273.19
Buy
90.60%
Upside
Reiterated
03/31/26
Wedbush Remains a Buy on AnaptysBio (ANAB)
Truist Financial Analyst forecast on MX:ANAB
Joon Lee
Truist Financial
Truist Financial
$611.13→$848.8
Hold
27.07%
Upside
Reiterated
03/09/26
Truist Financial Keeps Their Hold Rating on AnaptysBio (ANAB)
Guggenheim Analyst forecast on MX:ANAB
Yatin Suneja
Guggenheim
Guggenheim
$2,376.63
Buy
255.78%
Upside
Reiterated
03/04/26
Guggenheim Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Wells Fargo Analyst forecast on MX:ANAB
Derek Archila
Wells Fargo
Wells Fargo
$1,375.05
Buy
105.85%
Upside
Reiterated
12/16/25
AnaptysBio (ANAB) Receives a Buy from Wells Fargo
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
HITIHigh Tide
JAZZJazz Pharmaceuticals
OMCLOmnicell
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AnaptysBio

3 Months
Anupam RamaJ.P. Morgan
Success Rate
11/16 ratings generated profit
69%
Average Return
+22.82%
Copying Anupam Rama's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +22.82% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
12/16 ratings generated profit
75%
Average Return
+114.30%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +114.30% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
15/16 ratings generated profit
94%
Average Return
+202.04%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +202.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANAB Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
2
1
3
5
4
Buy
22
14
14
7
6
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
15
17
12
11
In the current month, ANAB has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ANAB average Analyst price target in the past 3 months is 1,438.71.
Each month's total comprises the sum of three months' worth of ratings.

ANAB Financial Forecast

ANAB Earnings Forecast

Next quarter’s earnings estimate for ANAB is -$0.85 with a range of -$1.19 to -$0.51. The previous quarter’s EPS was -$7.89. ANAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.
Next quarter’s earnings estimate for ANAB is -$0.85 with a range of -$1.19 to -$0.51. The previous quarter’s EPS was -$7.89. ANAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.

ANAB Sales Forecast

Next quarter’s sales forecast for ANAB is $273.69M with a range of $0.00 to $621.50M. The previous quarter’s sales results were ―. ANAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.
Next quarter’s sales forecast for ANAB is $273.69M with a range of $0.00 to $621.50M. The previous quarter’s sales results were ―. ANAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ANAB has Performed in-line its overall industry.

ANAB Stock Forecast FAQ

What is MX:ANAB’s average 12-month price target, according to analysts?
Based on analyst ratings, AnaptysBio Inc’s 12-month average price target is 1,438.71.
    What is MX:ANAB’s upside potential, based on the analysts’ average price target?
    AnaptysBio Inc has 115.38% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AnaptysBio Inc a Buy, Sell or Hold?
          AnaptysBio Inc has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is AnaptysBio Inc’s share price target?
            The average share price target for AnaptysBio Inc is 1,438.71. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,612.71 ,and the lowest forecast is $1,273.19. The average share price target represents 115.38% Increase from the current price of $668.
              What do analysts say about AnaptysBio Inc?
              AnaptysBio Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of AnaptysBio Inc?
                To buy shares of MX:ANAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.